Mosunetuzumab-a newly emerged hope in relapse or refractory B-cell lymphomas

Non-Hodgkin lymphoma (NHL), is type of cancer that begins in the lymphatic system which is part of our body’s immune defense system. Among this type the most prevalent is follicular lymphoma (FL) and is characterized by the aggregation or lump formation of abnormal lymphocytes either in the lymph nodes or other organs. This helps in identifying the tumor burden and the stage of FL. The risk to encounter cases with relapse or refractory disease is higher which may affect patient’s survival and hence quality of life (QoL). In the light of these patient challenges, it is important to introduce therapies that can directly target the specific sites and improve disease prognosis.